Pramiset 0.125 Tablet contains Pramipexole 0.125mg, a dopamine agonist commonly prescribed for the management of Parkinson’s disease and Restless Leg Syndrome (RLS). It helps compensate for dopamine deficiency in the brain, improving motor control, reducing tremors, stiffness, and improving movement coordination.
This medicine belongs to the Neurology and CNS segment, making it a widely prescribed product by neurologists and movement disorder specialists. Pramipexole is known for its role in early-stage Parkinson’s treatment and as an add-on therapy in advanced stages.
Due to long-term chronic treatment requirements, this product ensures high repeat demand, making it a profitable choice for PCD pharma franchise holders, wholesalers, and hospital suppliers.
Pramiset 0.125 Tablet is available for:
This product is a strong addition to any neurology portfolio with steady market demand and long-term prescription sustainability.
Common side effects may include dizziness, unsteady movement, sleepiness, nausea, gum swelling, and hair growth. Long-term use may rarely cause blood, liver, or bone changes. Dose-related side effects may occur if blood levels become high.
It is prescribed for tonic-clonic seizures, partial seizures, status epilepticus (emergency use), and certain arrhythmias, especially when associated with digitalis toxicity.
Do not stop the medication abruptly without medical supervision. Regular monitoring of blood levels, liver function, and dental hygiene may be required. Avoid alcohol and interactions with other medications unless approved by a doctor.
Store in a cool, dry place below 25°C, protected from direct sunlight and moisture. Keep out of reach of children.